GE HealthCare's MIM Software Gains FDA Clearance for Monte Carlo Dosimetry in Theranostics

GE HealthCareView company profile's MIM Software (search)Search term has secured FDA 510(k) clearance for its Monte Carlo dosimetry, a significant advancement poised to refine radiopharmaceutical therapy (search)Search drug (RPT) through precise dose calculation. This clearance allows the integration of Monte Carlo dosimetry via the Dose Planning Method (DPM) into MIM SurePlan MRT, MIM Software’s solution designed for automating and standardizing dosimetry in theranostics.

Advancing Personalized Medicine with Precise Dosimetry

Dosimetry plays a crucial role in radiotherapy by estimating the radiation dose absorbed by both healthy tissues and tumors, which helps in predicting the biological effects of radiation. As theranostics and RPT become increasingly vital in cancer (search)Search disease treatment, the ability to personalize these treatments through accurate dosimetry is paramount.

The Monte Carlo method is recognized as a gold standard for RPT dosimetry due to its high calculation accuracy, particularly in tissues with varying densities. The Dose Planning Method (DPM), developed and validated at the University of Michigan, simulates photons and electrons, further enhancing the precision of dose calculations.

Streamlining Clinical Workflows

Traditionally, Monte Carlo techniques have been considered time-intensive, often requiring several hours for calculations. However, MIM SurePlan MRT, incorporating DPM, can deliver rapid and accurate Monte Carlo dose calculations within seconds using existing hardware, eliminating the need for additional graphics processing units. This efficiency streamlines the dosimetry process, making it more clinically practical through automation and standardization.

Expert Perspectives

Yuni Dewaraja, PhD, Professor of Radiology at the University of Michigan, emphasized the importance of this advancement: "It is exciting that the Dose Planning Method code developed and validated at our institution will be available to the Theranostics community at large with the recent FDA clearance. This opens up the possibility for harmonized and accurate patient-specific dosimetry across centers, which can lead to robust dose-effect relationships, dosimetry-guided radiopharmaceutical therapy (search)Search drug, and ultimately a greater benefit for patients receiving these promising therapies."

Expanding Access to Theranostics

Andrew Nelson, CEO of MIM Software (search)Search term, GE HealthCareView company profile, highlighted the company's mission: "Enabling wide access to precise, personalized treatment options for cancer (search)Search disease is a key part of our mission. With the addition of Monte Carlo dosimetry for radiopharmaceutical therapy (search)Search drug, we are excited to offer healthcare organizations fast, accurate absorbed dose calculation without needing to acquire additional computer hardware. We hope this will ultimately increase the number of patients who have access to personalized Theranostics."

The integration of Monte Carlo dosimetry strengthens MIM SurePlan MRT's position as a comprehensive dosimetry solution, trusted by numerous healthcare facilities recognized as RPT Comprehensive Centers of Excellence by the Society of Nuclear Medicine & Molecular Imaging (SNMMI). This advancement is a significant step in GE HealthCareView company profile’s ongoing efforts to provide comprehensive solutions for theranostics, encompassing isotopes, imaging, informatics, molecular imaging agents, and digital tools.